Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) has announced a new AARP member benefit set to launch in January 2025, offering digital behavioral health and well-being solutions through Twill by Dario. This initiative aims to address growing mental health needs among people 50-plus, including issues like loneliness, stress, and anxiety. The benefit will provide AARP members with free access to Dario's premium Twill by Dario subscription service, along with a custom collection of 5 activity tracks.

Dario's user-centric platform has demonstrated success in driving engagement and positively impacting health by reducing symptoms of depression and loneliness, and improving overall perceptions of wellbeing. The company's technologies will offer personalized user navigation and simplify the process of recommending and implementing appropriate care and support modalities.

DarioHealth Corp. (Nasdaq: DRIO) has announced a new contract with a national Medicare Advantage health plan to launch its behavioral health solution, Twill by Dario, for plan members starting January 2025. This multi-million-dollar contract marks Dario's entry into the Medicare Advantage market and is expected to significantly contribute to the company's annual recurring revenue growth in 2025.

The partnership aims to support healthy aging by addressing emotional health and well-being, integrating capabilities to tackle Social Determinants of Health (SDoH). Dario's solution includes AI-based network navigation and tailored digital Cognitive Behavioral Therapy (CBT) programs designed for seniors.

This contract brings Dario's total health plan partnerships to seven, including four national health plans. The B2B2C channel now contributes over 70% of Dario's revenues as of Q1 2024, with expectations for continued growth.

DarioHealth Corp. (Nasdaq: DRIO) has announced a new contract with a national Medicare Advantage health plan to launch its behavioral health solution, Twill by Dario, for plan members starting January 2025. This marks Dario's fourth national health plan contract and first in the Medicare Advantage market, significantly expanding its footprint to over a million eligible members.

The Plan selected Dario to offer a single solution supporting healthy aging by addressing emotional health, well-being, and Social Determinants of Health (SDoH). Dario's AI-based network navigation will integrate support across community resources and health plan benefits. The solution includes tailored digital Cognitive Behavioral Therapy (CBT) programs designed for seniors.

This contract is expected to contribute significantly to Dario's annual recurring revenue growth in its Business-to-Business-to-Consumer (B2B2C) channel in 2025. The B2B2C channel currently contributes over 70% of Dario's revenues as of Q1 2024.

DarioHealth Corp. (Nasdaq: DRIO) has announced the integration of Twill's condition-specific communities and peer groups into its cardiometabolic solution. This integration aims to enhance member engagement and improve health outcomes for those managing chronic conditions such as diabetes, pre-diabetes, hypertension, and weight management.

The enhanced platform now offers:

• Peer-to-peer condition groups
• Access to healthcare experts
• Personalized educational content

This integration marks a significant milestone in the Dario-Twill product offering, leveraging social support to improve psychological well-being and overall health outcomes. Dario believes this approach will create one of the most comprehensive engagement platforms in the market, addressing the need for better adoption of digital health solutions.

DarioHealth Corp. (Nasdaq: DRIO) has published a new study in Frontiers in Endocrinology, demonstrating the effectiveness of its cardiometabolic solution for individuals with diabetes or prediabetes and depression. The research, involving 989 users over 12 months, reveals:

• Members with depression showed higher average blood glucose (BG) levels than those without
• Both groups experienced significant BG decreases in the first 4 months of platform usage
• A statistically significant association between depression status, BG levels, and average number of steps
• Monthly average steps fully mediate the association between self-reported depression and monthly average BG
• Users averaging over 400 steps daily showed significant decreases in monthly average BG

The study supports integrating walking into treatment protocols as a cost-effective intervention for glycemic control and depressive symptom alleviation in people with type 2 diabetes and depression.

DarioHealth reported Q2 2024 financial results with revenue of $6.26 million, up 8.6% from Q1 2024 and 1.7% year-over-year. The core B2B2C revenue channel saw 315% year-over-year growth to $5.5 million. The company is making progress on transforming its pharma channel to a recurring revenue model. DarioHealth expects to reduce operating expenses by 40% by Q1 2025 and reach cashflow breakeven by the end of 2025. The company ended Q2 with $22.9 million in cash. DarioHealth is seeing increased adoption of its GLP-1 product across clients seeking metabolic solutions. The company anticipates significant reductions in operating losses over the next three quarters driven by revenue growth and cost-cutting measures.

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics market, has announced it will release its financial results for the second quarter of 2024 on Thursday, August 8th, 2024, before the market opens. The company will host a conference call and webcast at 8:30 am Eastern Time on the same day.

The call will be hosted by Erez Raphael, CEO, and Steven Nelson, Chief Commercial Officer. Investors can join via phone or through a Call me™ link. A webcast will also be available. The replay of the call will be accessible until September 8th, 2024.

DarioHealth Corp. (Nasdaq: DRIO) has secured a new contract with a national employer to provide its cardiometabolic solution with integrated support for GLP-1s starting in Q3 2024. The solution addresses multiple health conditions, including diabetes, pre-diabetes, hypertension, and weight management.

Dario's platform is designed to drive sustainable behavior change, which is important for the success of GLP-1 medications, as 68% of users discontinue within a year. The company's enhanced engagement capabilities, bolstered by its acquisition of Twill, offer personalized journeys and behavioral support.

Dario expects at least ten employer clients to adopt its integrated offering in the coming quarter, leveraging its multi-chronic condition platform. The company sees growing interest from employers, payers, and pharmaceutical companies in its combined Dario-Twill solution for managing GLP-1 challenges.

New research presented by DarioHealth at the 84th Annual ADA Scientific Sessions demonstrates the efficacy of their digital health platform in sustaining behavior change for members taking GLP-1 medications. Data over a 12-month period show significant improvements in healthy lifestyle tracking and blood glucose control. Notably, 31% of Type 2 diabetes members achieved results consistent with diabetes remission. This research underscores the importance of combining GLP-1 medications with effective digital health solutions to maximize outcomes.